Ventoux Biosciences: Funding Rounds, Investors & CEO

About Ventoux Biosciences

Ventoux develops medicines for people with diseases where inflammation and scarring damage tissue. Its lead drug, VEN-201, is delivered at the disease site. The drug is intended as a first treatment for Dupuytren’s disease and to prevent recurrence after other treatment. Ventoux is also testing whether the local approach can reduce spinal-cord scarring and help damaged nerves recover. The candidate remains in preclinical development.

Kurt Harrington, a Dupuytren’s patient, founded Ventoux in October 2022 and serves as chief executive officer. Ventoux is based in Encinitas, California. In November 2025, it launched a spinal-cord injury program involving a UCLA professor acting as an independent academic researcher. Chief scientific officer Ken Lipson directs the program’s translational strategy.

Funding Rounds (SEC Form D)

First sale	Filed with SEC	Amount sold	Investors	Avg. check	Terms	Filing
Dec 27, 2023	Nov 12, 2026	$95,000fully sold	5	$19,000	Securities on exerciseRule 506(b)	Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Who Invested in Ventoux Biosciences

Scroll table to see all columns →

Announced	Round	Amount	Lead	Other investors	On the Form D	Source
Mar 12, 2024	Seed	Undisclosed	—	—		[6][7]

Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.

Why Investors Backed Ventoux Biosciences

Dupuytren’s is common and progressive, yet no approved medicine slows its course. Ventoux framed its seed-round case around a patient founder, a patented candidate and anti-fibrotic preclinical results. [6][7]

Origin and Team

Ventoux was founded in October 2022 by Kurt Harrington, a Dupuytren’s patient. Harrington has over 25 years of biopharmaceutical experience and previously worked at AstraZeneca and Biogen. His other employers included Amylin, which BMS acquired. He also worked at Cadence Pharmaceuticals, which Mallinckrodt Pharmaceuticals acquired. His experience also includes Avanir, which Otsuka Pharmaceutical acquired. [6][3]

Ken Lipson has more than 30 years in biotechnology and pharmaceuticals, with much of his research focused on fibrosis and cancer. Laxma Reddy has over 30 years in drug discovery, preclinical development and sustained-release delivery. [3]

Product and Technology

The lead candidate is a locally administered agent designed to change immune and scarring signals. It also targets extracellular matrix remodeling, the restructuring of tissue around cells. [5]

The spinal-cord injury program will test VEN-201 in animal models for effects on scarring, inflammation around nerves and tissue structure. [5]

Ventoux reported anti-fibrotic effects in a preclinical dermal-fibrosis model. It later built a human-tissue laboratory model to test VEN-201 and reported early results. [7][4]

The lead program emerged from AI-guided analysis of several layers of biological data. [1]

Use of Funds

The seed round will fund proof-of-concept testing of VEN-201 in human Dupuytren’s tissue. [6]
The seed round will fund optimization and testing of VEN-201’s long-acting formulation. [6]
The seed round will fund regulatory planning, FDA engagement and work on the intellectual-property portfolio. [6]

Milestones

Scroll table to see all columns →

Date	What happened	Source	Coverage
Nov 19, 2025	Ventoux launched a spinal-cord injury research program for VEN-201. Michael Sofroniew will conduct the work as an independent academic researcher.	[5]	—
Sep 23, 2025	Ventoux announced a U.S. patent covering a therapy for Dupuytren’s and other immune-fibrotic disorders. Protection runs through 2044.	[4]	FirstWord Pharma ↗Yahoo Finance ↗
2025	GHP Biotechnology Awards named Ventoux its 2025 Pre-Clinical Biopharmaceutical Company of the Year.	[4]	—
Dec 26, 2023	Ventoux appointed Ken Lipson chief scientific officer and vice president of corporate strategy.	[7]	—
Apr 25, 2023	Ventoux launched as a specialty pharmaceutical company for Dupuytren’s and related fibrotic diseases.	[8]	PharmaVoice ↗
2023	In the second quarter, Ventoux began preclinical evaluation of VEN-201 and VEN-202.	[8]	—

Market

Ventoux estimates Dupuytren’s affects 8.2% of people worldwide and more than 30 million people in the United States and Europe. It reports recurrence after surgery can reach 85%, while complication rates can reach 39%. [8]

We wrote this summary from public statements by Ventoux Biosciences and its investors. It is not investment advice.